生物活性:Ethambutol-d10 is the deuterium labeled Ethambutol. Ethambutol is a bacteriostatic antimycobacterial agent, which obstructs the formation of cell wall by inhibiting arabinosyl transferases.
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Ethambutol-d10 相关抗体:
MRP2 Antibody
Elongation factor 2 Antibody (YA962)
Elongation factor 2 Antibody (YA964)
PU.1/SPI1 Antibody (YA1116)
Sulfadimidine Antibody (YA906)
Elongation factor 2 Antibody (YA963)
Anthrax Protective gen Antibody (YA1060)
Elongation factor 1 gamma Antibody (YA2004)
Pulmonary Surfactant Associated Protein D Antibody (YA2107)
Cathelicidin Antibody (YA2380)
Elongation Factor Ts Antibody (YA2524)
Elongation Factor 1A2 Antibody (YA2879)
BPI Antibody (YA3068)
MetRS Antibody (YA3196)
分子量:214.37
Formula:C10H14D10N2O2
CAS 号:1129526-24-4
非标记 CAS:74-55-5
性状:固体
颜色:White to off-white
中文名称:乙胺丁醇-d10
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Powder:-20°C:3 years,4°C:2 years
In solvent:-80°C:6 months,-20°C:1 month
纯度 & 产品资料
纯度: ≥99.0%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]
[2]. Ethambutol. Tuberculosis (Edinb), 2008. 88(2): p. 102-5.
[Content Brief]
[3]. Rastogi, N., V. Labrousse, and K.S. Goh, In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol, 1996. 33(3): p. 167-75.
[Content Brief]
[4]. Kaur, D. and G.K. Khuller, In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria. Int J Antimicrob Agents, 2001. 17(1): p. 51-5.
[Content Brief]